The blood–brain barrier protects neural tissue by tightly regulating which substances can leave the bloodstream and enter the brain. While this defense is essential for preventing toxins and pathogens from reaching delicate neurons, it also blocks many potentially valuable drugs, including proteins, nucleic acids and some small-molecule therapies. As a result, treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, brain tumors, epilepsy and stroke may require high systemic doses, invasive administration or delivery methods that remain difficult to scale.

Intranasal administration has attracted intense interest because the upper nasal cavity provides anatomical connections to the brain through the olfactory and trigeminal nerve pathways. Drugs deposited near the olfactory epithelium may move along or around these pathways, potentially reaching regions of the central nervous system without first circulating throughout the body. This concept, often described as nose-to-brain delivery, could reduce systemic exposure and allow therapeutics to act more directly at their intended site. Yet the nasal route is not automatically efficient: mucus, enzymatic degradation, rapid clearance and limited absorptive surface area can all reduce the amount of medicine that reaches neural tissue.

The review focuses on autonomous systems engineered to respond to their biological surroundings rather than simply releasing a drug at a predetermined rate. These platforms may use nanoscale or microscale carriers that alter their behavior when they encounter changes in pH, temperature, enzymes, ionic strength or other features of the nasal environment. Some are designed to adhere temporarily to the nasal mucosa, extending residence time despite the constant movement of mucus toward the throat. Others can change their structure, swell, dissolve or release their cargo in response to local signals, creating a more controlled delivery profile.

Nanoparticles are central to many of these approaches. Lipid-based particles, polymeric nanoparticles, nanogels and other engineered carriers can protect fragile payloads from degradation and improve their interaction with nasal tissues. Surface chemistry is particularly important. By adding mucoadhesive components, researchers can help particles remain in contact with the epithelium; by incorporating mucus-penetrating coatings, they may enable carriers to move through the mucus layer and approach the underlying cells. The challenge is to balance these opposing properties, because excessive adhesion can trap a carrier in mucus while insufficient adhesion can lead to rapid removal.

Autonomous delivery systems may also be engineered to cross cellular barriers or release medicines only after reaching a particular biological compartment. For example, a carrier could protect a protein or messenger RNA during administration, promote uptake by nasal epithelial cells and then release its cargo inside the cell. Other designs aim to transport drugs along neuronal pathways or encourage passage through tissues surrounding the olfactory bulb. These strategies are especially relevant for biologics, whose large size and chemical instability make them difficult to deliver by traditional routes.

The technology could eventually support therapies that are difficult to administer using standard nasal sprays. Small-volume devices, precision nozzles and electronically controlled applicators may improve deposition in the upper nasal cavity, while smart formulations could respond to the local environment after administration. Some future systems may combine sensing, movement and drug release in a single platform, allowing them to adapt to patient-specific conditions such as mucus composition, inflammation or variations in nasal anatomy. Such “autonomous” behavior remains largely a research goal, but it reflects a broader shift toward delivery systems that actively manage their own interaction with the body.

Despite the promise, the review emphasizes that nose-to-brain delivery is accompanied by substantial biological and engineering challenges. The nasal cavity varies considerably between individuals, and factors including age, congestion, allergies, disease, breathing patterns and prior surgery can alter deposition and absorption. Much of an intranasal dose may still be swallowed or enter the bloodstream rather than reaching the brain. Researchers must also establish whether a drug detected in brain tissue arrived through a genuine neural pathway or simply crossed the blood–brain barrier after systemic absorption. Reliable imaging, pharmacokinetic measurements and standardized animal and human models will be essential for resolving this question.

Safety is another major consideration. Repeated exposure to nanoparticles, polymers or penetration-enhancing chemicals could irritate or damage the nasal epithelium, disrupt the sense of smell or trigger immune responses. Materials must be carefully evaluated for toxicity, biodegradability and long-term accumulation. Manufacturing presents an additional hurdle: complex multifunctional carriers must be produced consistently, sterilized without losing performance and packaged in devices that deliver accurate doses. Before autonomous intranasal systems can become routine clinical tools, they will require rigorous testing in humans to demonstrate reproducible brain targeting, meaningful therapeutic benefit and acceptable safety.

The review presents intranasal delivery as more than a convenient alternative to injections. By combining biomaterials science, nanotechnology, neurobiology and device engineering, autonomous systems could create a new generation of brain-targeted medicines capable of protecting sensitive cargo, overcoming mucosal barriers and releasing therapy in response to local conditions. The field is still moving from sophisticated laboratory prototypes toward clinically validated products, but its central ambition is clear: to make treatment of the brain less invasive, more precise and more adaptable to the complex biology of each patient.

Subject of Research: Autonomous intranasal delivery systems for transporting therapeutics to the central nervous system

Article Title: Autonomous intranasal delivery systems for central nervous system therapeutics

Article References: Shen, H., Srivastava, S.K., Aggarwal, N. et al. Autonomous intranasal delivery systems for central nervous system therapeutics. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01781-5

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01781-5

Keywords: intranasal drug delivery, nose-to-brain delivery, central nervous system therapeutics, blood–brain barrier, nanomedicine, autonomous delivery systems, nanoparticles, neurotherapeutics

Addressing this challenge, contemporary research has delved deeply into the development of innovative drug delivery vehicles capable of traversing the BBB. Among the most promising advances are nanocarriers — minuscule, engineered particles designed to ferry drugs safely and effectively across this biological blockade. By leveraging the unique physicochemical properties of nanoparticles, these delivery systems enhance bioavailability within the CNS, allowing for more targeted and sustained therapeutic effects.

Various nanomaterial platforms have been engineered to fulfill this role, each with distinct characteristics. Polymeric nanoparticles capitalize on their biocompatibility and controlled-release capabilities, making them versatile candidates for drug encapsulation. Liposomes, lipid-based vesicles, mimic cellular membranes to facilitate fusion and drug transport into the brain, improving uptake and stability. Solid-lipid nanoparticles offer another approach, combining lipid biocompatibility with structural rigidity to protect therapeutic molecules during circulation.

Quantum dots, semiconductor nanocrystals with fluorescent properties, present an exciting avenue for not only delivering drugs but also monitoring their distribution and interaction within neural tissues in real time. Their unique optical features afford researchers unprecedented insight into CNS pharmacokinetics, paving the way for precision nanomedicine.

Despite promising preclinical results and initial clinical explorations, the translation of these nanocarriers into widespread therapeutic use faces considerable hurdles. Safety concerns remain paramount; the long-term biocompatibility and potential immunogenicity of nanoparticles must be rigorously evaluated. Moreover, large-scale manufacturing and reproducibility of these complex nanostructures challenge current pharmaceutical production paradigms.

Scalability presents a twofold problem: first, ensuring that nanoparticle synthesis maintains the precise physical and chemical properties critical for functionality; second, establishing cost-effective methodologies that can be adopted globally. These challenges underscore the crucial need for interdisciplinary collaboration between nanotechnologists, pharmacologists, toxicologists, and regulatory bodies.

The therapeutic potential unlocked by combining traditional pharmacological approaches with nanotechnology could revolutionize how CNS disorders are treated. By overcoming the BBB’s limitations, these novel drug carriers promise enhanced delivery efficiency, reduced systemic side effects, and improved patient compliance through targeted and controlled-release mechanisms.

Emerging research also highlights the importance of surface modifications on nanoparticles, such as the attachment of ligands and antibodies, which facilitate receptor-mediated transport across the BBB. This targeting strategy exploits natural cellular pathways, enabling more precise drug localization and minimizing off-target interactions.

In addition to drug delivery, nanocarriers are being explored for their ability to carry gene therapy vectors and neuroprotective agents, broadening their therapeutic applicability. Such versatility could herald new treatment paradigms for complex neurodegenerative diseases, autoimmune CNS disorders, and brain tumors.

While these advancements are indeed encouraging, it is clear that the promise of nanocarriers in CNS therapeutics requires further validation through extensive clinical trials. Translational research must address safety profiles, dosing regimens, pharmacodynamics, and long-term outcomes to ensure these innovations can be effectively adopted in clinical settings.

Therefore, the ongoing convergence of nanotechnology and pharmacology stands as a pivotal frontier in neuroscience. Continued investment in this domain holds profound implications for alleviating the burden of neurological diseases, potentially transforming the landscape of CNS drug delivery and patient care.

As the scientific community advances in decoding the intricacies of BBB penetration and nanocarrier design, the vision of precise, effective, and safe treatments for CNS disorders moves closer to realization. This synthesis of disciplines exemplifies the future trajectory of biomedical innovation—a future where technology and medicine coalesce to overcome previously insurmountable challenges.

Subject of Research: Advances in drug nanocarriers for delivery to the central nervous system (CNS) overcoming the blood-brain barrier (BBB).

Article Title: Recent advances in potential drug nanocarriers for CNS disorders: a review

Article References:
Saraswathi, T.S., Mothilal, M., Bukke, S.P.N. et al. Recent advances in potential drug nanocarriers for CNS disorders: a review.
BioMed Eng OnLine 24, 137 (2025). https://doi.org/10.1186/s12938-025-01474-6

Image Credits: AI Generated

DOI: 21 November 2025